InvestorsHub Logo
Followers 163
Posts 8738
Boards Moderated 1
Alias Born 04/10/2012

Re: badshah post# 8619

Monday, 03/30/2020 2:21:48 PM

Monday, March 30, 2020 2:21:48 PM

Post# of 63388
Regarding the patent issued in Australia of BRT-100 is worth as much as the industry of disc and spine related issues, everyone has some back problems, workers in any field from construction, to wearhouse work, postal workers, enforcement officers, athletes...you name it, that alone could be millions.

https://www.globenewswire.com/news-release/2019/10/23/1934189/0/en/BioRestorative-Therapies-Receives-A-Second-Patent-in-Australia-For-Its-Metabolic-Program.html

MELVILLE, N.Y., Oct. 23, 2019 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (the “Company") (OTC: BRTX), a life sciences company focused on stem cell-based therapies, today announced that the Australia Patent Office has issued a Certificate of Grant for the Company’s patent application titled “Human Brown Adipose Derived Stem Cells and Uses.”

This is the second patent issued for the Company’s brown fat technology in Australia and adds to three other patents related to BioRestorative’s metabolic program (ThermoStem® Program) that have previously been issued to the Company in the United States and other countries.



Disc/Spine Program (brtxDISC™): Our lead cell therapy candidate, BRTX-100, is a product formulated from autologous (or a person’s own) cultured mesenchymal stem cells collected from the patient’s bone marrow. We intend that the product will be used for the non-surgical treatment of painful lumbosacral disc disorders. The BRTX-100 production process utilizes proprietary technology and involves collecting a patient’s bone marrow, isolating and culturing stem cells from the bone marrow and cryopreserving the cells. In an outpatient procedure, BRTX-100 is to be injected by a physician into the patient’s damaged disc. The treatment is intended for patients whose pain has not been alleviated by non-invasive procedures and who potentially face the prospect of surgery. We have received authorization from the Food and Drug Administration to commence a Phase 2 clinical trial using BRTX-100 to treat persistent lower back pain due to painful degenerative discs.


C4urself the 1st Ammendment.
Don't assume that i don't know, and i wont assume, that you have no idea.

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent BRTX News